Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908257 · ClinicalTrials.gov registry record · Phase 1
Lesinurad Interaction Study With Ranitidine
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01908257: Completed Phase 1 study, sponsored by Ardea Biosciences.
NCT01908257 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01908257, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of ranitidine on lesinurad.
Primary Outcome
Profile in terms of Cmax, Tmax, AUC, CL/F, t1/2 Cmax: maximum concentration; Tmax: time to reach max plasma concentration; AUC: area under the concentration-time curve; CL/F: total body clearance corrected for bioavailability; t1/2: apparent terminal half-life
Interventions
- DRUG lesinurad 400 mg
- DRUG ranitidine 150 mg
- DRUG lesinurad 400 mg + ranitidine 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01908257 record still lists
NCT01908257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which lesinurad 400 mg is the first listed.
NCT01908257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01908257 about?
NCT01908257 is a clinical study titled "Lesinurad Interaction Study With Ranitidine". This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of ranitidine on lesinurad.
What is the current status of trial NCT01908257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01908257?
The interventions under investigation include: lesinurad 400 mg (DRUG), ranitidine 150 mg (DRUG), lesinurad 400 mg + ranitidine 150 mg (DRUG).
Who is sponsoring clinical trial NCT01908257?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01908257's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia